Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia
Purpose Following the emergency use authorization of BNT162b2 by the Food and Drug administration (FDA) in early December 2020, mRNA- and vector-based vaccines became an important means of reducing the spread and mortality of the COVID-19 pandemic. The European Medicines Agency labelled immune thrombocytopenia (ITP) as a rare adverse reaction of unknown frequency after vector-, but not mRNA-vaccination. Here, we report on the long-term outcome of 6 patients who were diagnosed with de-novo, vaccine-associated ITP (VA-ITP), and on the outcome of subsequent SARS-CoV-2 re-vaccinations. Methods Patients were included after presenting to our emergency department. Therapy was applied according to ITP guidelines. Follow-up data were obtained from outpatient departments. Both mRNA- or vector-based vaccines were each used in 3 cases, respectively. Results In all patients, the onset of symptoms occurred after the 1st dose of vaccine was applied. 5 patients required treatment, 3 of them 2nd line therapy. All patients showed a complete response eventually. After up to 359 days of follow-up, 2 patients were still under 2nd line therapy with thrombopoietin receptor agonists. 5 patients have been re-vaccinated with up to 3 consecutive doses of SARS-CoV-2 vaccines, 4 of them showing stable platelet counts hereafter. Conclusion Thrombocytopenia after COVID-19 vaccination should trigger a diagnostic workup to exclude vaccine-induced immune thrombotic thrombocytopenia (VITT) and, if confirmed, VA-ITP should be treated according to current ITP guidelines. Re-vaccination of patients seems feasible under close monitoring of blood counts and using a vaccine that differs from the one triggering the initial episode of VA-ITP..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Infection - 51(2022), 1 vom: 04. Okt., Seite 231-238 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ruzicka, Michael [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1007/s15010-022-01909-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR049157175 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR049157175 | ||
| 003 | DE-627 | ||
| 005 | 20230519161125.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230127s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s15010-022-01909-5 |2 doi | |
| 035 | |a (DE-627)SPR049157175 | ||
| 035 | |a (SPR)s15010-022-01909-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ruzicka, Michael |e verfasserin |0 (orcid)0000-0002-2451-1070 |4 aut | |
| 245 | 1 | 0 | |a Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Purpose Following the emergency use authorization of BNT162b2 by the Food and Drug administration (FDA) in early December 2020, mRNA- and vector-based vaccines became an important means of reducing the spread and mortality of the COVID-19 pandemic. The European Medicines Agency labelled immune thrombocytopenia (ITP) as a rare adverse reaction of unknown frequency after vector-, but not mRNA-vaccination. Here, we report on the long-term outcome of 6 patients who were diagnosed with de-novo, vaccine-associated ITP (VA-ITP), and on the outcome of subsequent SARS-CoV-2 re-vaccinations. Methods Patients were included after presenting to our emergency department. Therapy was applied according to ITP guidelines. Follow-up data were obtained from outpatient departments. Both mRNA- or vector-based vaccines were each used in 3 cases, respectively. Results In all patients, the onset of symptoms occurred after the 1st dose of vaccine was applied. 5 patients required treatment, 3 of them 2nd line therapy. All patients showed a complete response eventually. After up to 359 days of follow-up, 2 patients were still under 2nd line therapy with thrombopoietin receptor agonists. 5 patients have been re-vaccinated with up to 3 consecutive doses of SARS-CoV-2 vaccines, 4 of them showing stable platelet counts hereafter. Conclusion Thrombocytopenia after COVID-19 vaccination should trigger a diagnostic workup to exclude vaccine-induced immune thrombotic thrombocytopenia (VITT) and, if confirmed, VA-ITP should be treated according to current ITP guidelines. Re-vaccination of patients seems feasible under close monitoring of blood counts and using a vaccine that differs from the one triggering the initial episode of VA-ITP. | ||
| 650 | 4 | |a Immune thrombocytopenia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Vaccine-associated ITP |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Post-vaccinal ITP |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 vaccine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Wurm, Sonja |0 (orcid)0000-0002-7540-737X |4 aut | |
| 700 | 1 | |a Lindner, Lars |0 (orcid)0000-0003-3708-8264 |4 aut | |
| 700 | 1 | |a Dreyling, Martin |0 (orcid)0000-0002-0358-5249 |4 aut | |
| 700 | 1 | |a von Bergwelt-Baildon, Michael |0 (orcid)0000-0002-1952-052X |4 aut | |
| 700 | 1 | |a Boeck, Stefan |0 (orcid)0000-0002-1922-2127 |4 aut | |
| 700 | 1 | |a Giessen-Jung, Clemens |4 aut | |
| 700 | 1 | |a Milani, Valeria |4 aut | |
| 700 | 1 | |a Stemmler, Joachim H. |0 (orcid)0000-0001-8751-8555 |4 aut | |
| 700 | 1 | |a Subklewe, Marion |0 (orcid)0000-0001-9154-9469 |4 aut | |
| 700 | 1 | |a Weigert, Oliver |0 (orcid)0000-0002-0987-7373 |4 aut | |
| 700 | 1 | |a Spiekermann, Karsten |0 (orcid)0000-0002-5139-4957 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection |d München : Urban & Vogel, 1973 |g 51(2022), 1 vom: 04. Okt., Seite 231-238 |w (DE-627)SPR032536909 |w (DE-600)2006315-5 |x 1439-0973 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2022 |g number:1 |g day:04 |g month:10 |g pages:231-238 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s15010-022-01909-5 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2022 |e 1 |b 04 |c 10 |h 231-238 | ||